Latest Commercial Rollouts News

GreenHy2 Limited has raised nearly $1 million through a strategic share placement aimed at expanding its PowerSafe Sodium-Ion and Lithium-Ion battery offerings. Part of the placement awaits shareholder approval at the upcoming AGM.

Memphasys Limited has secured Therapeutic Goods Administration approval for its Felix™ System two months ahead of schedule, enabling immediate commercial sales and clinical use in Australia.

Memphasys has raised $800,000 through a share placement to accelerate the commercial expansion of its Felix™ System, following key regulatory approvals and initial revenue milestones.

Imricor Medical Systems has taken a significant step toward US market entry by submitting its Advantage-MR EP Recorder/Stimulator system for FDA 510(k) clearance, aiming to enhance MRI-guided cardiac procedures.

Cyclopharm Limited is accelerating its US market push for Technegas with a A$16 million capital raise following a record 2025 sales performance. The company aims to expand its US installations and advance new clinical applications beyond pulmonary embolism.

Sparc Technologies and the Australian Institute for Machine Learning are developing AI-driven software to transform protective coatings corrosion assessment, promising faster, more accurate results for a global market of testing labs.

Rhythm Biosciences has secured a multi-year commercial manufacturing agreement with US-based Quansys Biosciences to produce ColoSTAT® reagent kits, paving the way for broader market rollout of its colorectal cancer diagnostic test.

EVE Health Group has transitioned from development to commercial rollout, delivering first patient prescriptions of Dyspro™ and completing initial manufacturing of Libbo™, supported by a $1.1 million capital raise.

4DMedical Limited has responded to ASX queries over its announcements of commercial agreements with leading US academic medical centres, clarifying its disclosure approach and denying ramping allegations ahead of a $150 million capital raise.

Klevo Rewards Ltd has successfully reinstated its ASX listing, completed a $3.4 million capital raise, and made significant progress on its digital wallet and loyalty platform. The company’s improved cash position and operational momentum set the stage for its next growth phase.

HeraMED has secured pivotal US commercial agreements and achieved a key Australian regulatory milestone, positioning itself for scalable growth in digital maternity care.

EVE Health Group has completed manufacturing and distribution setup for Libbo™, its innovative oral dissolving film for erectile dysfunction, paving the way for near-term patient access via telehealth and pharmacy channels.